Fierce Pharma Asia—Bispecific field's roller coaster week; Enhertu's first-line win; Regeneron-Hansoh obesity deal
5th June 2025 Uncategorised 0The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. AstraZeneca and Daiichi Sankyo trotted out Enhertu’s detailed data in first-line breast cancer. Regeneron signed on a GLP-1/GIP candidate from Hansoh Pharma. And more.
More: Fierce Pharma Asia—Bispecific field's roller coaster week; Enhertu's first-line win; Regeneron-Hansoh obesity deal
Source: fierce